CoChat

The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway

Open access
‘t Hart, Leen M., Fritsche, Andreas, Nijpels, Giel, van Leeuwen, Nienke, Donnelly, Louise A., Dekker, Jacqueline M., Alssema, Marjan, Fadista, Joao, Carlotti, Françoise, Gjesing, Anette P., Palmer, Colin N.A., van Haeften, Timon W., Herzberg-Schäfer, Silke A., Simonis-Bik, Annemarie M.C., Houwing-Duistermaat, Jeanine J., Helmer, Quinta, Deelen, Joris, Guigas, Bruno, Hansen, Torben, Machicao, Fausto, Willemsen, Gonneke, Heine, Robert J., Kramer, Mark H.H., Holst, Jens J., de Koning, Eelco J.P., Häring, Hans-Ulrich, Pedersen, Oluf, Groop, Leif, de Geus, Eco J.C., Slagboom, P. Eline, Boomsma, Dorret I., Eekhoff, Elisabeth M.W., Pearson, Ewan R., Diamant, Michaela · 2013 · Diabetes
Cited by 102

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances β-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30–40%) on GLP-1–stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤ 8.8 × 10−7). rs7202877 near CTRB1/2, a known diabetes risk locus, also associated with an absolute 0.51 ± 0.16% (5.6 ± 1.7 mmol/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but there was no effect on GLP-1 RA treatment in type 2 diabetic patients (n = 527). Furthermore, in pancreatic tissue, we show that rs7202877 acts as expression quantitative trait locus for CTRB1 and CTRB2, encoding chymotrypsinogen, and increases fecal chymotrypsin activity in healthy carriers. Chymotrypsin is one of the most abundant digestive enzymes in the gut where it cleaves food proteins into smaller peptide fragments. Our data identify chymotrypsin in the regulation of the incretin pathway, development of diabetes, and response to DPP-4 inhibitor treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db13-0227

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 102

Metadata

Authors
‘t Hart, L. M., Fritsche, A., Nijpels, G., van Leeuwen, N., Donnelly, L. A., Dekker, J. M., Alssema, M., Fadista, J., Carlotti, F., Gjesing, A. P., Palmer, C. N. A., van Haeften, T. W., Herzberg-Schäfer, S. A., Simonis-Bik, A. M. C., Houwing-Duistermaat, J. J., Helmer, Q., Deelen, J., Guigas, B., Hansen, T., Machicao, F., Willemsen, G., Heine, R. J., Kramer, M. H. H., Holst, J. J., de Koning, E. J. P., Häring, H.-U., Pedersen, O., Groop, L., de Geus, E. J. C., Slagboom, P. E., Boomsma, D. I., Eekhoff, E. M. W., Pearson, E. R., & Diamant, M.
Venue
Diabetes
Published
2013-08-15
Volume
62
Issue
9
Pages
3275-3281
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2154438179
Cited by
102
References
12
FWCI
6.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway. https://app.cochat.ai/papers/10.2337/db13-0227
The paper
‘t Hart, L. M., Fritsche, A., Nijpels, G., van Leeuwen, N., Donnelly, L. A., Dekker, J. M., Alssema, M., Fadista, J., Carlotti, F., Gjesing, A. P., Palmer, C. N. A., van Haeften, T. W., Herzberg-Schäfer, S. A., Simonis-Bik, A. M. C., Houwing-Duistermaat, J. J., Helmer, Q., Deelen, J., Guigas, B., Hansen, T., . . . Diamant, M. (2013). The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway. Diabetes. https://doi.org/10.2337/db13-0227

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.